Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carfilzomib pharmacokinetics and safety in advanced malignancies with varying hepatic impairment
NL-OMON41294Phase 1Active, not recruiting
- Sponsor
- Amgen
- Start
- May 2014
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of carfilzomib in advanced nonhematological malignancy and hematopoietic malignancies (4 cohorts), sponsored by Amgen. Primary endpoint: Carfilzomib AUC at Cycle 1 Day 16. Started May 2014; status: active, not recruiting.
02
Drugs
carfilzomib
03
Conditions
advanced nonhematological malignancyhematopoietic malignancies
Beyond the preview
Go deeper on NL-OMON41294.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41294.